生长激素作为心力衰竭的生物标志物

Growth Hormone as Biomarker in Heart Failure.

作者信息

Marra Alberto M, Bobbio Emanuele, D'Assante Roberta, Salzano Andrea, Arcopinto Michele, Bossone Eduardo, Cittadini Antonio

机构信息

IRCCS SDN, Via Gianturco, 113, 80143 Naples, Italy.

Department of Translational Medical Sciences, Federico II University, Via Pansini, 5, 80131 Naples, Italy.

出版信息

Heart Fail Clin. 2018 Jan;14(1):65-74. doi: 10.1016/j.hfc.2017.08.008.

DOI:10.1016/j.hfc.2017.08.008

PMID:29153202

Abstract

The impairment of growth hormone (GH)/insulin growth factor-1(IGF-1) plays a crucial role in chronic heart failure (CHF). Several studies have shown that patients affected by this condition display a more aggressive disease, with impaired functional capacity and poor outcomes. Interestingly, GH replacement therapy represents a possible future therapeutic option in CHF. In this review, the authors focus on the assessment of the main abnormalities in GH/IGF-1 axis in CHF, the underlying molecular background, and their impact on disease progression and outcomes.

摘要

生长激素（GH）/胰岛素样生长因子-1（IGF-1）受损在慢性心力衰竭（CHF）中起关键作用。多项研究表明，受这种疾病影响的患者表现出更具侵袭性的病情，功能能力受损且预后较差。有趣的是，生长激素替代疗法是慢性心力衰竭未来可能的治疗选择。在这篇综述中，作者重点评估了慢性心力衰竭中生长激素/胰岛素样生长因子-1轴的主要异常、潜在的分子背景及其对疾病进展和预后的影响。